NEW YORK, Dec. 5 (GenomeWeb News) - Stratagene signed a licensing agreement with Focus Diagnostics to market molecular diagnostics products based on its FullVelocity technology, the company said today.
Under the terms of the agreement, Focus Diagnostics will receive a non-exclusive license to Stratagene's FullVelocity technology, and Stratagene will help the company develop molecular diagnostic testing kits and products. Stratagene will manufacture any diagnostics products that arise from the collaboration, and Focus will commercialize these products globally.
Strategene will also manufacture and sell reagents to Focus that will be used in the company's national reference laboratory.
Financial details were not disclosed.
FullVelocity is a high-speed reagent system for quantitative PCR and QRT-PCR that enables users to make numerous copies of a target to detect the presence of specific DNA and RNA in medical specimens.